FIELD: medicine.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to treatment of small cell lung cancer. A method for treating small cell lung cancer in a subject, including administering a synergistic combined therapy to the subject, including 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-on and cisplatin. A synergistic combination of 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-on and cisplatin for treating small cell lung cancer.
EFFECT: described method and combination are effective in treating small cell lung cancer by means of synergistic combined therapy.
6 cl, 22 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| SYNERGISTIC COMBINATIONS OF AURISTANE | 2015 |
|
RU2717570C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2662436C2 |
| COMBINATION OF PROTEIN KINASE INHIBITOR AND ADDITIONAL CHEMOTHERAPEUTIC AGENT | 2017 |
|
RU2785997C1 |
| METHODS OF TREATMENT | 2020 |
|
RU2822394C1 |
| PHARMACEUTICAL COMBINATIONS | 2013 |
|
RU2674995C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
